Kaiser Health News, in its latest update to its campaign contributions tracking tool, reports that Senator Chris Coons, D-Delaware, received the most contributions from the pharmaceutical industry during the first half of 2019, at $103,000. Coons, together with Senator Thom Tillis, R-North Carolina, who himself received $102,000 this cycle, released a draft of a patent reform bill in May, and concerns among drug makers about the eventual passage of that bill have run high.
While the US election is more than 1 year away, drug makers on both the biosimilar and innovator sides of the industry are hoping to see their interests represented and are giving substantial sums to sitting lawmakers.
Kaiser Health News (KHN), in its latest update to its campaign contributions tracking tool, reports that Senator Chris Coons, D-Delaware, received the most contributions from the pharmaceutical industry during the first half of 2019, at $103,000.
One potential reason for that significant influx of cash is the fact that Coons, together with Senator Thom Tillis, R-North Carolina, who himself received $102,000 this cycle, released a draft of a patent reform bill in May, and concerns among drug makers about the eventual passage of that bill have run high.
The proposed legislation seeks to update the legal standard for patent eligibility and, say the senators, guard against overly broad patent claims that could be abused. The bill would change the law in response to recent Supreme Court decisions that established a test for evaluating patent eligibility, and it would explicitly define “useful” inventions that would give courts a new standard to determine whether a patent is directed toward eligible subject matter.
According to the American Bar Association (ABA), currently, the patent system is rife with uncertainty and unpredictability and creates unacceptable risks for innovators. The ABA says that it supports the Coons and Tillis reforms as a means to reduce risk to entrepreneurs. However, the Coalition Against Patent Abuse, which has members that include Blue Cross Blue Shield, the biosimilar and generic group the Association for Accessible Medicines, and America’s Health Insurance Plans, says that the bill “empowers Big Pharma at the expense of everyday Americans,” and urges Congress to reject the legislation.
KHN’s data also reveal that the drug maker that has engaged in the most spending in 4 of the past 7 election cycles is biosimilar developer Pfizer, which has given more than $8 million in total and $263,886 this cycle. Fellow biosimilar developer Mylan, which will merge with Pfizer’s Upjohn unit, increased its spending this cycle, giving $113,000, or more than it gave in the previous 2 years combined.
The Association for Accessible Medicines gave $12,500 to 8 lawmakers this cycle, while the innovator drug group Biotechnology Innovation Organization gave $102,673 to more than 50 lawmakers. Innovator drug group the Pharmaceutical Research Manufacturers of America, or PhRMA, gave $71,500 this cycle to more than 50 lawmakers.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.